Sort by
Refine Your Search
-
congress planning, the fellow will engage in global cross-functional collaboration, contribute to the communication of emerging science, and support the strategic dissemination of data that advances patient
-
Number: 6840828 Alnylam Pharmaceuticals-Clinical Science Postdoctoral Research Fellow About the Opportunity About the Opportunity Northeastern University Pharmaceutical Industry Fellowships Program is a
-
, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio's pipeline of development programs ranges from early science to advanced clinical trials
-
analyze glucose levels. Our science-driven products empower people living with diabetes. Through our innovative product development program, Abbott has developed many cutting-edge glucose monitoring
-
medicines with the potential to transform the lives of people afflicted with rare and more prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically
-
development and post-marketing research, HCP and patient interactions, scientific publications, field materials, sponsorships, grants. Fellow activity will often involve working cross-functionally with teams
-
new class of innovative medicines with the potential to transform the lives of people afflicted with rare and more prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a
-
biology, including neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, primary membranous, nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes, and myotonic dystrophy
-
in medical information, medical communications & publications, field-based US medical science liaison and promotional review committee and will also have the opportunity to specialize in a preferred
-
the potential to transform the lives of people afflicted with rare and more prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach